Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;29(6):883-887.
doi: 10.1093/ibd/izac174.

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD

Dalin Li  1 , Philip Debbas  1 , Angela Mujukian  1 , Susan Cheng  2 , Jonathan Braun  1 , Dermot P B McGovern  1 , Gil Y Melmed  1 ; CORALE-IBD Study Group
Collaborators, Affiliations

Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD

Dalin Li et al. Inflamm Bowel Dis. .

Abstract

Background: The safety of a third dose of SARS-CoV-2 mRNA vaccination in patients with inflammatory bowel disease is unknown.

Methods: We compared symptoms following a third SARS-CoV-2 mRNA vaccine dose with symptoms after the second dose in IBD.

Results: The study group included 594 patients (70% female, 58% BNT162b2). Overall, 41% reported symptoms after a third dose. Symptom frequency and severity were lower after the third dose relative to the second dose for every organ system, except for gastrointestinal symptoms which were marginally worse.

Conclusion: The frequency and severity of symptoms after a third mRNA vaccine dose are generally similar or milder than after a second dose for most organ systems.

Plain language summary

The postvaccination symptom profile in patients with IBD is unknown after a third mRNA COVID vaccine dose. In a cohort of 594 subjects with IBD, we demonstrated that 41% experienced any symptoms after a third dose, the vast majority of which were mild and lasted less than 2 days. Symptoms after third dose were less frequently reported than after the second dose.

PubMed Disclaimer

Conflict of interest statement

G.Y.M. has consulted for AbbVie, Arena Pharmaceuticals, Boehringer-Ingelheim, Bristol-Myers Squibb/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, and Techlab and has received research funding from Pfizer for an unrelated investigator-initiated study. J.B. has received research funding from Janssen. J.C.P., J.L.S., and E.C.F. work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study. D.P.B.M.: Bridge Biotherapeutics, Gilead, Palatin, Pfizer, Promteheus Biosciences, Prometheus Laboratories, Takeda. M.C.: Abbvie, Arena, Bristol-Meyers Squibb, Janssen, Medtronic, Pfizer, and Takeda. E.C.: Abbvie and Pfizer. D.F.: Pfizer. C.H.: Abbvie, Janssen and Pfizer. D.L.: Abbvie, Janssen and Takeda. R.M.: Abbvie, Bristol Myers Squibb, Pfizer, and Prometheus Bioscience. N.P.: Pfizer. DW: Abbvie, Arena, Bristol Meyers Squibb, Corevitas, Janssen, Lilly, Pfizer, and Takeda. B.M.: Abbvie, Bristol Myers Squibb, Janssen, Pfizer and Takeda. S.G.: Abbvie, Janssen, and Takeda. C.H.: Abbvie, Bristol Meyers Squibb, Genentech, InbDex Pharmaceuticals, Janssen, Lilly, and Pfizer. G.S.: research funding for unrelated investigator study from Pfizer. S.T.: Prometheus Bioscience.

The remaining authors have no competing interests.

Figures

Figure 1.
Figure 1.
Severity of symptoms by system for dose 3 relative to dose 2.
See this image and copyright information in PMC

Update of

References

    1. Dalal RS, McClure E, Marcus J, et al. COVID-19 vaccination intent and perceptions among patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(8):1730-1732. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. - PMC - PubMed
    1. Botwin GJ, Li D, Figueiredo J, et al. Adverse events following SARS-CoV-2 mRNA vaccination: among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116(8):1746-1751. - PMC - PubMed
    1. Weaver KN, Zhang X, Dai X, et al. Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from Prevent-Covid. Inflamm Bowel Dis. 2021. Online ahead of print. - PMC - PubMed

Publication types